---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-260671"
form_type: "8-K"
ticker: "SPTX"
cik: "0002042347"
company_name: "Seaport Therapeutics, Inc."
filed_at: "2026-06-08T11:11:42+00:00"
generated_at: "2026-06-08T11:17:48.391434+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track

## Summary
- Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.
- Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.
- GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.
- GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.
- Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds.

## SEC filing metadata
- accession: 0001193125-26-260671
- form_type: 8-K
- ticker: SPTX
- cik: 0002042347
- company_name: Seaport Therapeutics, Inc.
- filed_at: 2026-06-08T11:11:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/0001193125-26-260671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/sptx-20260608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-260671
- JSON: https://secwatch.observer/filing/0001193125-26-260671.json
- Plain text: https://secwatch.observer/filing/0001193125-26-260671.txt

## Key facts
- Earnings Releases
  Seaport Therapeutics, Inc. reported financial results for the first quarter of 2026.
  - Period: the first quarter of 2026
  - Result: reported results
  source text: today announced financial results for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/0001193125-26-260671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.